Scientists have discovered a novel approach to potentially slow memory loss in Alzheimer's disease, a condition that affects millions worldwide. According to a recent study published in the Proceedings of the National Academy of Sciences (https://www.pnas.org/doi/10.1073/pnas.2521944123), researchers at Cold Spring Harbor Laboratory in New York have uncovered a crucial role of an enzyme called PTP1B in memory decline in mice with Alzheimer's.
The study's lead researcher, Professor Nicholas Tonks, has been studying PTP1B since its discovery in 1988. Tonks and his team found that reducing PTP1B activity enhances the brain's immune cells, known as microglia, in clearing amyloid-β (Aβ) plaques, which are protein build-ups associated with Alzheimer's disease. As the disease progresses, these microglia become less effective at removing debris, leading to memory decline.
The study reveals that PTP1B interacts with a protein called spleen tyrosine kinase (SYK), which regulates microglia's response to damage and their ability to clear Aβ. By inhibiting PTP1B, the researchers suggest that they can improve microglial function, potentially slowing down the progression of Alzheimer's.
Interestingly, PTP1B is already known for its role in metabolic conditions like obesity and type 2 diabetes, which are recognized risk factors for Alzheimer's. This discovery opens up a new pathway for treatment, as the laboratory is now working on developing PTP1B inhibitors for various applications.
Tonks envisions a combination therapy that pairs existing approved drugs with PTP1B inhibitors to slow Alzheimer's progression and improve patients' quality of life. Cholinesterase inhibitors like donepezil and NMDA receptor antagonists such as memantine are currently used to treat Alzheimer's, but the goal is to find more effective solutions.
With over 55 million people living with dementia globally, and Alzheimer's disease accounting for up to 70% of cases, the need for innovative treatments is urgent. As Tonks, whose mother lived with Alzheimer's, notes, this disease is a slow and gradual process of losing a person piece by piece. The discovery of this new pathway offers hope for a brighter future for those affected by this devastating condition.
